Literature DB >> 16091284

A biochemical analysis of topoisomerase II alpha and beta kinase activity found in HIV-1 infected cells and virus.

Anand K Kondapi1, Gade Padmaja, N Satyanarayana, Robin Mukhopadyaya, Marvin S Reitz.   

Abstract

Human topoisomerase II plays a crucial role in DNA replication and repair. It exists in two isoforms: topoisomerase II alpha (alpha) and topoisomerase II beta (beta). The alpha isoform is localized predominantly in the nucleus, while the beta isoform exhibits a reticular pattern of distribution both in the cytosol and in the nucleus. We show that both isoforms of topoisomerase II are phosphorylated in HIV infected cells and also by purified viral lysate. An analysis of the phosphorylation of topoisomerase II isoforms showed that extracts of HIV infected cells at 8 and 32 h. post-infection (p.i.) contain maximal phosphorylated topoisomerase II alpha, whereas infected cell extracts at 4 and 64 h p.i. contain maximum levels of phosphorylated topoisomerase II beta. In concurrent to phosphorylated topoisomerase II isoforms, we have also observed increased topoisomerase II alpha kinase activity after 8h p.i and topoisomerase beta kinase activity at 4 and 64 h p.i. These findings suggest that both topoisomerase II alpha and beta kinase activities play an important role in early as well as late stages of HIV-1 replication. Further analysis of purified virus showed that HIV-1 virion contained topoisomerase II isoform-specific kinase activities, which were partially isolated. One of the kinase activities of higher hydrophobicity can phosphorylate both topoisomerase II alpha and beta, while lower hydrophobic kinase could predominantly phosphorylate topoisomerase II alpha. The phosphorylation status was correlated with catalytic activity of the enzyme. Western blot analysis using phosphoamino-specific antibodies shows that both the kinase activities catalyze the phosphorylation at serine residues of topoisomerase II alpha and beta. The catalytic inhibitions by serine kinase inhibitors further suggest that the alpha and beta kinase activities associated with virus are distinctly different.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091284     DOI: 10.1016/j.abb.2005.06.021

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  4 in total

1.  Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.

Authors:  Ekram M Saleh
Journal:  Tumour Biol       Date:  2015-06-17

2.  WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.

Authors:  Dale M Walker; Adriana E Kajon; Salina M Torres; Meghan M Carter; Consuelo L McCash; James A Swenberg; Patricia B Upton; Andrew W Hardy; Ofelia A Olivero; Gene M Shearer; Miriam C Poirier; Vernon E Walker
Journal:  Environ Mol Mutagen       Date:  2009-07       Impact factor: 3.216

3.  Detection of the Epstein-Barr virus and DNA-topoisomerase II- α in recurrent and nonrecurrent giant cell lesion of the jawbones.

Authors:  Manal M Zyada; Nagla M Salama
Journal:  Biomed Res Int       Date:  2013-07-15       Impact factor: 3.411

4.  Global post-translational modification profiling of HIV-1-infected cells reveals mechanisms of host cellular pathway remodeling.

Authors:  Jeffrey R Johnson; David C Crosby; Judd F Hultquist; Andrew P Kurland; Prithy Adhikary; Donna Li; John Marlett; Justine Swann; Ruth Hüttenhain; Erik Verschueren; Tasha L Johnson; Billy W Newton; Michael Shales; Viviana A Simon; Pedro Beltrao; Alan D Frankel; Alexander Marson; Jeffery S Cox; Oliver I Fregoso; John A T Young; Nevan J Krogan
Journal:  Cell Rep       Date:  2022-04-12       Impact factor: 9.995

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.